Old Web
English
Sign In
Acemap
>
authorDetail
>
K. Egan
K. Egan
Novartis
Nilotinib
Phases of clinical research
Immunology
Internal medicine
Median follow-up
3
Papers
28
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Analysis of the GeneXpert System on the International Multicentre ICORG 08–02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML),
2011
Blood
Michael O’Dwyer
Ronan T Swords
Francis J. Giles
Mary Frances McMullin
P. le Coutre
Arnon Nagler
Stephen E. Langabeer
M. Wieczorkowska
C. McDowell
K. Egan
B. Moulton
Eibhlin Conneally
Show All
Source
Cite
Save
Citations (3)
Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph Positive Chronic Myeloid Leukemia In Chronic Phase Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR ABL RQ PCR
2010
Blood
Eibhlin Conneally
Ronan T Swords
Francis J. Giles
Mary Frances McMullin
P. le Coutre
Stephen E. Langabeer
M. Wieczorkowska
C. McDowell
B. Moulton
K. Egan
Michael O’Dwyer
Show All
Source
Cite
Save
Citations (8)
Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study
2009
Blood
Michael O’Dwyer
E. Kent
M Parker
Ronan T Swords
Francis J. Giles
P. le Coutre
Swaminathan Padmanabhan
B. Moulton
Mary Frances McMullin
Stephen E. Langabeer
K. Egan
Eibhlin Conneally
Show All
Source
Cite
Save
Citations (17)
1